Cartesian Therapeutics (RNAC) EBITDA (2015 - 2026)

Cartesian Therapeutics (RNAC) has reported EBITDA for 12 consecutive years, with -$26.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBITDA fell 21.06% year-over-year to -$26.5 million; the TTM figure through Mar 2026 stood at -$148.0 million (down 182.27% YoY), while the FY2025 annual figure was -$143.4 million, down 226.69% from the prior year.
• EBITDA grew to -$26.5 million in Q1 2026 per RNAC's latest filing, from -$78.6 million in the prior quarter.
• Across five years, EBITDA topped out at $13.9 million in Q2 2022 and bottomed at -$78.6 million in Q4 2025.
• Historically, EBITDA has averaged -$16.8 million across 5 years, with a median of -$18.4 million in 2023.
• Annual changes were most pronounced in 2022 — EBITDA surged 2966.37% — and 2023, when it plunged 717.07%.
• Cartesian Therapeutics' EBITDA stood at -$8.5 million in 2022, then sank by 327.64% to -$36.3 million in 2023, then climbed by 26.43% to -$26.7 million in 2024, then plunged by 194.19% to -$78.6 million in 2025, then surged by 66.3% to -$26.5 million in 2026.
• Business Quant data shows RNAC's EBITDA at -$26.5 million in Q1 2026, -$78.6 million in Q4 2025, and -$21.1 million in Q3 2025.